The study design of the effectiveness analysis is weak. In particular, the comparability of the groups in terms of age, sex and prognostic features was not evaluated by the authors. Moreover, no power calculations were given. A sensitivity analysis would have been useful to generalise the costs results to other institutional settings, since drug local prices were used.